ArticleNeurology2016
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
Nicholas Schwab et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ArticleNeurology2016
Nicholas Schwab et al.PubMed ↗Publisher ↗
No numbers read from the abstract.